GSA Capital Partners’s Gyre Therapeutics GYRE Stock Holding History

GSA Capital Partners’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-23,433	Closed	-$722K	–	1561
2021 Q3	$722K	Buy	23,433 +828	+4%	+$27.2K	0.07%	479
2021 Q2	$734K	Buy	22,605 +19,147	+554%	+$657K	0.08%	385
2021 Q1	$131K	Buy	3,458 +1,773	+105%	+$81K	0.02%	977
2020 Q4	$80K	Buy	+1,685	New	+$73K	0.01%	1116
2020 Q1	–	Sell	-4,540	Closed	-$232K	–	1248
2019 Q4	$232K	Buy	+4,540	New	+$190K	0.03%	1180
2019 Q3	–	Sell	-5,403	Closed	-$299K	–	1514
2019 Q2	$299K	Buy	+5,403	New	+$338K	0.03%	1008
2018 Q4	–	Sell	-42,655	Closed	-$3.45M	–	1501
2018 Q3	$3.45M	Buy	42,655 +21,702	+104%	+$1.72M	0.19%	59
2018 Q2	$1.83M	Buy	+20,953	New	+$3.68M	0.09%	322

Other funds holding GYRE

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

GSA Capital Partners's GYRE Position: Q4 2021 in Review

GSA Capital Partners sold out of Gyre Therapeutics (GYRE) in Q4 2021, closing a stake of 23,433 shares — an estimated $722K sold.

GSA Capital Partners first reported a position in GYRE in Q2 2018 and held it in 8 quarters. The position peaked at $3.45M in Q3 2018. 51 funds tracked by Wall St. Rank hold GYRE as of Q4 2021.

GSA Capital Partners reported no remaining Gyre Therapeutics position as of Q4 2021 after selling out during the quarter.
GSA Capital Partners sold 23,433 Gyre Therapeutics shares in Q4 2021, an estimated $722K.
GSA Capital Partners first reported a position in Gyre Therapeutics in Q2 2018 and held it in 8 quarters.
GSA Capital Partners's Gyre Therapeutics position peaked at $3.45M in Q3 2018.
51 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2021.

Based on GSA Capital Partners's 13F filing for Q4 2021, filed 14 Feb 2022.